此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin (PRaCTISe-HR)

2026年11月16日 更新者:Tuberculosis Research Centre, India

A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin

This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.

研究概览

详细说明

Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)

研究类型

介入性

注册 (估计的)

2500

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
  • 电话号码:044 2836 9518
  • 邮箱:narendra.ng@icmr.gov.in

学习地点

    • Andhra Pradesh
      • Guntur、Andhra Pradesh、印度、522503
        • 招聘中
        • All India Institute of Medical Sciences(AIIMS), Mangalagiri
        • 接触:
    • Assam
      • Guwahati、Assam、印度、781101
        • 主动,不招人
        • All India Institute of Medical Sciences, Guwahati
    • Gujarat
      • Rajkot、Gujarat、印度、360001
        • 尚未招聘
        • Govt. PDU Medical College
        • 接触:
      • Surat、Gujarat、印度、395001
        • 主动,不招人
        • Govt. Medical College and NCH
    • Maharashtra
      • Mumbai、Maharashtra、印度、400008
        • 招聘中
        • Grant Govt. Medical College & Sir JJ Group of Hospitals
        • 接触:
      • Nagpur、Maharashtra、印度
        • 尚未招聘
        • All India Institute Of Medical Sciences, Nagpur
        • 接触:
    • Meghālaya
      • Shillong、Meghālaya、印度、793018
        • 招聘中
        • North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
        • 接触:
    • National Capital Territory of Delhi
      • New Delhi、National Capital Territory of Delhi、印度、110030
        • 尚未招聘
        • National Institute of TB and Respiratory Diseases
        • 接触:
    • Odisha
      • Bhubaneswar、Odisha、印度、751019
        • 主动,不招人
        • All India Institute of Medical Sciences (AIIMS), Bhubaneswar
      • Bhubaneswar、Odisha、印度、751001
        • 主动,不招人
        • Post Graduate Institute of Medical Education & Research, Capital Hospital
    • Tamil Nadu
      • Chennai、Tamil Nadu、印度、600031
        • 招聘中
        • ICMR - National Institute for Research in Tuberculosis
        • 接触:
        • 接触:
        • 首席研究员:
          • Dr PK Bhavani, MBBS., MPH., PGDBEME
        • 首席研究员:
          • Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
        • 副研究员:
          • Dr R Balaji, MBBS., MD.,
    • Telangana
      • Hyderabad、Telangana、印度、500038
        • 招聘中
        • Govt. General and Chest Hospital, Osmania Medical College
        • 接触:
    • Uttar Pradesh
      • Agra、Uttar Pradesh、印度、282002
        • 招聘中
        • Sarojini Naidu Medical College
        • 接触:
      • Allahābād、Uttar Pradesh、印度、211002
        • 招聘中
        • Moti Lal Nehru Medical College
        • 接触:
      • Lucknow、Uttar Pradesh、印度、226003
        • 招聘中
        • King George Medical University
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

14年 至 70年 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Individuals aged equal or above 14 years.
  2. Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
  3. Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
  4. If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
  5. Willing to follow the trial procedures

Exclusion Criteria:

  1. Body weight less than 30 kg in adults

  2. Anti-TB treatment, >14 days for the current illness

  3. Known Resistance to rifampicin & Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA

  4. Patients with serious forms of Extra-pulmonary TB

  5. HIV Patients on second line ART regimens.

  6. Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities

    • ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
    • Serum Creatinine >1.2 mg/dl.
  7. Pregnant or lactating mothers

  8. Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability

  9. Patients with h/o of concomitant medications which may interfere with study drugs

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:2H R25 ZE /4 H R10 E

Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol

Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs.

Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs.

实验性的:2 H R25 ZE/ 4 H R25 E

Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol

Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol

Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs.

Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs.

实验性的:2 H R25 ZE L/2 H R25 E L

Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg)

Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin.

Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs.

有源比较器:2 H R10 ZE /4H R10 E

Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol

Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol

Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
大体时间:Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization

次要结果测量

结果测量
措施说明
大体时间
Proportion of patients with grade 3 or 4 adverse drug reactions.
大体时间:Through treatment completion, an average of 24 weeks
Through treatment completion, an average of 24 weeks
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
大体时间:Through treatment completion, an average of 24 weeks
Through treatment completion, an average of 24 weeks
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
大体时间:At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
大体时间:At 1st Month
At 1st Month
The cost effectiveness of different treatment regimens
大体时间:Through treatment completion, an average of 24 weeks

Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB.

Through treatment completion, an average of 24 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Dr PK Bhavani, MBBS., MPH., PGDBEME、ICMR - National Institute for Research in Tuberculosis
  • 首席研究员:Dr G Narendran, MBBS., DNB., DTRD., FRCP.,、ICMR - National Institute for Research in Tuberculosis

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月6日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2029年12月1日

研究注册日期

首次提交

2026年11月9日

首先提交符合 QC 标准的

2026年11月16日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅